Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 4 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Mythic Therapeutics Inc. has 4 pending office actions in the Biotechnology & Pharmaceuticals technology area. These matters are distributed across 4 distinct art units. The prosecution involves the distinct examiner DUFFY, BRADLEY, who is the busiest examiner and is responsible for 1 pending office action. With 4 pending actions handled by different examiners, the prosecution workload is evenly distributed across the portfolio.
The management of 4 pending office actions across 4 art units requires a versatile legal strategy within the Biotechnology & Pharmaceuticals field. Each examiner may have different preferences and examination styles, necessitating a tailored approach for each application. The presence of DUFFY, BRADLEY as the busiest examiner with 1 pending office action shows that no single individual is overwhelmed by the current portfolio activity. This decentralized structure allows the company to pursue multiple technological paths simultaneously. Practitioners should be diligent in tracking the progress across the 4 distinct art units to ensure that all deadlines are met. The focus on Biotechnology & Pharmaceuticals provides a common technical framework for these separate prosecution efforts.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 2 (50%) |
| Double-patenting + other | 1 (25%) |
| Multi-statute (no §101) | 1 (25%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| DUFFY, BRADLEY | 1 | 54.5% | +45.8% |
| XIAO, YAN | 1 | 67.3% | +52.7% |
| PETRASH, HILARY ANN | 1 | 64.5% | +51.7% |
| GUSTILO, ESTELLA M | 1 | 53.6% | +34.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17616744 | ANTIGEN-BINDING PROTEIN CONSTRUCTS AND USES THEREOF | GUSTILO, ESTELLA M | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17624467 | ANTIGEN-BINDING PROTEIN CONSTRUCTS AND USES THEREOF | PETRASH, HILARY ANN | 22d |
| 17765153 | ANTIGEN-BINDING PROTEIN CONSTRUCTS AND USES THEREOF | XIAO, YAN | 70d |
| 18273078 | ANTI-MET ANTIBODIES AND USES THEREOF | DUFFY, BRADLEY | — |
| 17616744 | ANTIGEN-BINDING PROTEIN CONSTRUCTS AND USES THEREOF | GUSTILO, ESTELLA M | — |
| Art Unit | Apps |
|---|---|
| 1643 | 1 |
| 1642 | 1 |
| 1644 | 1 |
| 1646 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18273078 | ANTI-MET ANTIBODIES AND USES THEREOF | DUFFY, BRADLEY | 1643 | §112DP | Non-Final OA | — | Pending | Jul 19, 2023 |
| 17765153 | ANTIGEN-BINDING PROTEIN CONSTRUCTS AND USES THEREOF | XIAO, YAN | 1642 | §112 | Non-Final OA | 70d | Pending | Mar 30, 2022 |
| 17624467 | ANTIGEN-BINDING PROTEIN CONSTRUCTS AND USES THEREOF | PETRASH, HILARY ANN | 1644 | §112 | Final Rejection | 22d | Pending | Jan 03, 2022 |
| 17616744 | ANTIGEN-BINDING PROTEIN CONSTRUCTS AND USES THEREOF | GUSTILO, ESTELLA M | 1646 | §103§112Other | Final Rejection | — | Pending | Dec 06, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial